China’s National Medical Products Administration (NMPA) has approved the marketing application for Linzess (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China.
US biotech firm Ironwood Pharmaceuticals (Nasdaq: IRWD), whose shares jumped 6.19% to $13.03 on the news, anticipates that it will launch the drug with its partner in China, UK-headquartered AstraZeneca (LSE: AZN), in the second half of 2019.
Linaclotide is a guanylate cyclase-C (GC-C) receptor agonist currently approved and available for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC) in the United States and more than 30 other countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze